{"ATC Code":"N05BA08","Abbreviation":"","Aliases":["Compedium","Durazanil","Lectopam","Lexotan","Creosedin","Lekotam","Lexaurin","Lexilium","Calmepam","Compendium"],"Biological Half-Life":"10-20 hours","CAS":"1812-30-2","ChEBI":"CHEBI:31302","ChEMBL":"CHEMBL277062","ChemicalClasses":["benzodiazepine"],"Chirality":"achiral","Classes":null,"DEA no":2748,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anti-Anxiety Agents; Benzodiazepines; GABA Modulators; Hypnotics and Sedatives","Drug Indication":"For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.","DrugClasses":["antidepressant","depressant"],"EINECS":"217-322-4","EliminationHalfLife":"12–20 hours (avg. 17hr)\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e","Erowid Experience Reports":[{"Id":"101368","Title":"Interacting With Others Is Very Difficult"},{"Id":"110173","Title":"Very sedative"},{"Id":"111014","Title":"Watch Out for Your Cognitive and Motor Skills"},{"Id":"45709","Title":"Very Positive Reaction"},{"Id":"61623","Title":"Chemical Jesus"},{"Id":"62198","Title":"Reduces My Anxiety Without Too Much Sedation"},{"Id":"62706","Title":"Blurry Memory"},{"Id":"64906","Title":"A Gradual Onset"},{"Id":"66861","Title":"Decent Stuff But Not My Favorite"},{"Id":"68374","Title":"This Medication Gave Nothing but Trouble"},{"Id":"68026","Title":"Two Faced, Relaxed and Enraged"},{"Id":"69500","Title":"Doesn't Make Me Especially Sleepy or Rubbery"},{"Id":"73506","Title":"Calmness and Mild Euphoria"},{"Id":"71483","Title":"A Good Chang-Up"},{"Id":"76592","Title":"I Discovered These Little Pink Pill"},{"Id":"77491","Title":"Fighting a Lifetime of Anxiety"},{"Id":"84751","Title":"By Far My Favorite"},{"Id":"85845","Title":"My Love Affair"},{"Id":"91040","Title":"Insignificant and Pointless"},{"Id":"91713","Title":"Man I Love This pink..."},{"Id":"98211","Title":"7 Days Off-Line"}],"European Community (EC) Number":"217-322-4","HMDB ID":"HMDB0015511","HeavyAtomCount":19,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anti-Anxiety Agents; Benzodiazepines; GABA Modulators; Hypnotics and Sedatives","IUPACName":"7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one","Impurities":["2-(2-amino-5-bromobenzoyl)pyridine","2(1h)-quinolinone, 3-amino-6-bromo-4-(2-pyridinyl)-","2-bromo-n-(4-bromo-2-picolinoylphenyl)acetamide","6-methyl bromazepam","n-(4-bromo-2-(2-pyridylcarbonyl)phenyl)-2-chloroacetamide"],"InChI":"InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)","InChIKey":"VMIYHDSEFNYJSL-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)","MolecularFormula":"C\u003csub\u003e14\u003c/sub\u003eH\u003csub\u003e10\u003c/sub\u003eBrN\u003csub\u003e3\u003c/sub\u003eO","MolecularWeight":"316.15 g/mol","Pharmacodynamics":"Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.","Physical Description":"Solid","PrevSalts":[],"PubChemId":2441,"Record Description":["Bromazepam is an organic molecular entity.","Bromazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.","BROMAZEPAM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for anxiety and has 3 investigational indications.","Bromazepam is only found in individuals that have used or taken this drug. It is one of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances.Bromazepam binds to the GABA receptor GABA\u003csub\u003eA\u003c/sub\u003e, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.","One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.","Bromazepam is an organic molecular entity."],"RefCount":5,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Bromazepam","Name":"Bromazepam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q422435","Name":"Bromazepam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01558","Name":"Bromazepam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2441","Name":"Bromazepam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL277062","Name":"Bromazepam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31302","Name":"Bromazepam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=1812-30-2","Name":"Bromazepam","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015511","Name":"Bromazepam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D01245","Name":"Bromazepam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/X015L14V0O","Name":"Bromazepam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID40171081","Name":"Bromazepam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 2441, Bromazepam. Accessed June 25, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/2441\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/2441\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Bromazepam. UNII: X015L14V0O. Global Substance Registration System. Accessed June 25, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/X015L14V0O\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/X015L14V0O\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 25, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e","Lexotan (bromazepam) Product Insert. Roche. October 23, 2012. Accessed June 25, 2025. \u003ca href=http://e-lactancia.org/media/papers/Bromazepam-DS-2012.pdf\u003ehttp://e-lactancia.org/media/papers/Bromazepam-DS-2012.pdf\u003c/a\u003e"],"SMILES":"C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=N3","Scheduling":[{"gov":"Brazil","ref":["3"],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"gov":"United Kingdom","ref":[],"schedule":"Class C substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"}],"Solubility":"3.99e-02 g/L","StoreUNII":["X015L14V0O"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="91.507mm" version="1.2" viewBox="0 0 84.688 91.507" width="84.688mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="92.0" stroke="none" width="85.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="78.944" x2="72.34" y1="28.691" y2="14.975"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="71.023" x2="78.444" y1="14.668" y2="5.406"/>
                        
                <line x1="72.926" x2="80.347" y1="16.193" y2="6.931"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="78.444" x2="74.73349999999999" y1="5.405999999999999" y2="10.036999999999999"/>
                <line class="hi" stroke="#FF0D0D" x1="80.347" x2="76.6365" y1="6.931000000000001" y2="11.562000000000001"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="72.34" x2="60.81" y1="14.975" y2="12.29"/>
                  
            <line class="bond" id="mol1bnd4" x1="54.474" x2="45.619" y1="13.957" y2="21.071"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="45.619" x2="45.619" y1="36.311" y2="21.071"/>
                        
                <line x1="43.18" x2="43.18" y1="34.903" y2="22.479"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="45.619" x2="32.411" y1="36.311" y2="43.931"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="19.203" x2="32.411" y1="36.311" y2="43.931"/>
                        
                <line x1="21.641" x2="32.411" y1="34.903" y2="41.116"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="19.203" x2="19.203" y1="36.311" y2="21.071"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="32.411" x2="19.203" y1="13.451" y2="21.071"/>
                        
                <line x1="32.411" x2="21.641" y1="16.266" y2="22.479"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="45.619" x2="32.411" y1="21.071" y2="13.451"/>
                  
            <line class="bond" id="mol1bnd11" x1="19.203" x2="7.771" y1="36.311" y2="42.913"/>
                  
            <line class="bond" id="mol1bnd12" x1="45.619" x2="57.506" y1="36.311" y2="45.861"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="57.506" x2="69.035" y1="45.861" y2="43.176"/>
                        
                <line x1="58.108" x2="68.482" y1="43.217" y2="40.802"/>
                      
                <line class="hi" stroke="#3050F8" x1="69.035" x2="63.2705" y1="43.176" y2="44.5185"/>
                <line class="hi" stroke="#3050F8" x1="68.482" x2="63.295" y1="40.802" y2="42.0095"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="78.944" x2="74.127" y1="28.691" y2="38.696"/>
                  
            <line class="bond" id="mol1bnd15" x1="57.506" x2="54.121" y1="45.861" y2="60.721"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="65.295" x2="54.121" y1="71.084" y2="60.721"/>
                        
                <line x1="62.604" x2="53.495" y1="71.914" y2="63.466"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="65.295" x2="61.9" y1="71.084" y2="85.95"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="47.332" x2="61.9" y1="90.452" y2="85.95"/>
                        
                <line x1="47.957" x2="59.836" y1="87.707" y2="84.035"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="47.332" x2="36.158" y1="90.452" y2="80.089"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="38.681" x2="36.158" y1="69.038" y2="80.089"/>
                        
                <line x1="41.058" x2="38.848" y1="69.581" y2="79.259"/>
                      
                <line class="hi" stroke="#3050F8" x1="38.681" x2="37.4195" y1="69.038" y2="74.5635"/>
                <line class="hi" stroke="#3050F8" x1="41.058" x2="39.953" y1="69.581" y2="74.42"/>
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="54.121" x2="42.831" y1="60.721" y2="64.21"/>
                  
            <path class="atom" d="M84.128 3.078q-.0 .756 -.256 1.328q-.256 .565 -.757 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.501 .309 .757 .875q.256 .565 .256 1.327zM80.264 3.078q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" id="mol1atm3" stroke="none"/>
                  
            <g class="atom" id="mol1atm4">
                        
                <path d="M59.447 13.97h-.721l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" stroke="none"/>
                        
                <path d="M59.31 8.509h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.071h2.512v-2.071h.619v4.899z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M1.959 40.906q.917 -.0 1.387 .274q.47 .268 .47 .94q.0 .435 -.244 .721q-.238 .285 -.69 .363v.036q.309 .047 .559 .178q.25 .131 .393 .375q.149 .238 .149 .619q.0 .667 -.458 1.03q-.459 .363 -1.245 .363h-1.72v-4.899h1.399zM2.078 42.995q.631 .0 .863 -.202q.238 -.202 .238 -.601q.0 -.405 -.285 -.578q-.286 -.178 -.911 -.178h-.81v1.559h.905zM1.173 43.507v1.774h.988q.655 .0 .905 -.25q.256 -.256 .256 -.666q.0 -.381 -.268 -.619q-.262 -.239 -.94 -.239h-.941zM6.649 42.061q.101 -.0 .22 .012q.125 .006 .208 .029l-.071 .554q-.089 -.018 -.196 -.03q-.108 -.017 -.203 -.017q-.28 -.0 -.53 .154q-.244 .155 -.393 .435q-.148 .274 -.148 .649v1.958h-.602v-3.673h.494l.066 .667h.03q.178 -.298 .458 -.518q.28 -.22 .667 -.22z" fill="#A62929" id="mol1atm11" stroke="none"/>
                  
            <path class="atom" d="M74.28 44.857h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M41.493 67.673h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.055h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" id="mol1atm19" stroke="none"/>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="60.81" x2="66.575" y1="12.29" y2="13.6325"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="60.81" x2="66.575" y1="12.29" y2="13.6325"/>
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="54.474" x2="50.046499999999995" y1="13.957" y2="17.514000000000003"/>
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="54.474" x2="50.046499999999995" y1="13.957" y2="17.514000000000003"/>
            <line class="hi" id="mol1bnd11" stroke="#A62929" x1="7.771000000000001" x2="13.487" y1="42.913" y2="39.611999999999995"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="74.127" x2="76.5355" y1="38.696" y2="33.6935"/>
            <line class="hi" id="mol1bnd21" stroke="#3050F8" x1="42.831" x2="48.476" y1="64.21" y2="62.46549999999999"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Bromazepam","UNII":"X015L14V0O","Wikidata":"Q422435","Wikipedia":"Bromazepam","XLogP":1.7}